Pf311 Isolated Primary Adrenal Lymphoma (Ipal) ‐ an Emerging Lymphoma Entity? Results of a Retrospective Multicenter Study

Abstract

Background:In April 2017 the first biosimilar rituximab (Truxima ® ; NAPP) was approved in the UK for all indications of the reference biologic (MabThera ® ; Roche). The adoption of biosimilars is expected to deliver significant cost savings in the treatment of many conditions. The approval of Truxima ® was based on comprehensive analytical and pre-clinical testing together with confirmatory clinical trials in advanced follicular lymphoma and rheumatoid arthritis with subsequent extrapolation to all licensed indications of MabThera ® .